<DOC>
	<DOCNO>NCT01181986</DOCNO>
	<brief_summary>The purpose investigation evaluate whether exenatide , type 2 diabetes medication , improve function innermost part arterial wall call endothelium fat-enriched meal determine occur . The result study help determine understand novel action group diabetes medication base action naturally occur gut substance call incretins . This may significant impact cardiovascular health patient early longstanding diabetes .</brief_summary>
	<brief_title>The Study Exenatide Action Vessel Function Type 2 Diabetes Prediabetes</brief_title>
	<detailed_description>Two independent , double-blinded , crossover substudies conduct test effect exenatide daylong post-meal fast endothelial function . We measure endothelial function measure peripheral arterial tonometry ( EndoPAT2000 , Itamar Inc. ) . Patients recent onset ( &lt; 3 year ) establish ( &gt; 5 year , Substudy 1 ) diabetes impair sugar tolerance ( Substudy 2 ) study . The plan complete study 75 patient ( 40 Substudy 1 35 Substudy 2 ) . In Substudy 1 patient get twice day skin injection exenatide ( Byetta ) identically look placebo 10 day , separate 14-day period . On next day treatemnt period ( day 11 ) , get one injection eat fat-enriched breakfast . A fatty lunch similar caloric content give 4 hour follow breakfast . Endothelial function measure prior injection every 2 hour total 8 hour . In Substudy 2 , patient 3 different day get infusion exenatide withg without block drug exendin-9 , control test placebo without exendin-9 . Endothelial function measure infusion 2 hour later final 15 minute infusion cocktail . Patients eat meal test visit .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<criteria>US Veterans type 2 diabetes mellitus ( T2D ) diagnose within 3 year good glycemic control diet , metformin , sulfonylurea agent combination agent ( HbA1c ≤8.0 % ) T2D diagnose ≥ 5 year prior study enrollment Impaired glucose tolerance T2D meeting inclusion criterion duration diabetes HbA1c value know suspected T1D ( early onset age , low body mass index , lack family history ) TZD use prior 3 month prior regular use insulin Creatinine &gt; 2.0 mg/dl laboratory clinical evidence kidney disease anemia know active liver disease hepatic enzyme elevation twoanda half time normal acute bacterial viral illness evidence active infection past 4 week stable unstable angina major illness past 6 month Raynaud 's disease rheumatic disease affect finger current regular use antiinflammatory medication antioxidant , include counter medication high dose salicylate ( &gt; 1 g/day ) ; subject receive lipid lower antihypertension medication must stable dos least 2 month prior participation .</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Type 2 diabetes mellitus , Impaired glucose tolerance</keyword>
</DOC>